Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Retroviruses02:33

Retroviruses

12.1K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.1K
Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Subviral Agents01:29

Subviral Agents

933
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
933
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

43.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.

Drugs of today (Barcelona, Spain : 1998)·2020
Same author

Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.

Drugs of today (Barcelona, Spain : 1998)·2020
Same author

Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.

Drugs of today (Barcelona, Spain : 1998)·2019
Same author

Cognitive biases and knowledge deficits leading to delayed recognition of cryptococcal meningitis.

IDCases·2019
Same author

Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.

Drugs of today (Barcelona, Spain : 1998)·2019
Same author

Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.

Drugs of today (Barcelona, Spain : 1998)·2019

Related Experiment Video

Updated: May 3, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Simeprevir: a macrocyclic HCV protease inhibitor.

R Talwani1, E L Heil2, B L Gilliam1

  • 1Institute of Human Virology and Division of Infectious Diseases, University of Maryland Medical Center, Baltimore, Maryland, USA.

Drugs of Today (Barcelona, Spain : 1998)
|February 14, 2014
PubMed
Summary

Simeprevir, a hepatitis C virus (HCV) protease inhibitor, effectively treats genotype 1 infections when combined with pegylated interferon and ribavirin. This combination achieved sustained virological response in over 75% of treatment-naive patients.

Keywords:
GT-1Hepatitis C virusMacrolideSimeprevirTMC-435

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

9.9K

Related Experiment Videos

Last Updated: May 3, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

9.9K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection remains a significant global health concern.
  • HCV protease inhibitors are crucial in developing effective antiviral therapies.
  • Simeprevir is a novel macrocyclic NS3/4A HCV protease inhibitor.

Purpose of the Study:

  • To evaluate the safety and efficacy of simeprevir in combination therapy for HCV.
  • To assess the sustained virological response (SVR) rates in treatment-naive patients with HCV genotype 1.

Main Methods:

  • Phase II and III clinical studies were conducted.
  • Simeprevir was administered orally once daily (150 mg).
  • Combination therapy included simeprevir, pegylated interferon (peg-IFN), and ribavirin (RBV).

Main Results:

  • The combination of simeprevir, peg-IFN, and RBV demonstrated a favorable safety profile.
  • More than 75% of treatment-naive patients achieved a sustained virological response (SVR).
  • Simeprevir exhibits moderate drug interaction potential, lower than first-generation inhibitors.

Conclusions:

  • Simeprevir in combination with peg-IFN/RBV is a safe and effective treatment for HCV genotype 1 infections.
  • The drug received regulatory approval in Japan, the U.S., and Canada in late 2013.
  • Ongoing Phase II studies are investigating interferon-free regimens with simeprevir.